Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Sarcoma 2Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 2Colorectal Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Rectal Neoplasms 1Neuroblastoma 1Neoplasms by Site 1Neoplasms by Histologic Type 1Liver Neoplasms 1Laryngeal Diseases 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1

Interventions

Bevacizumab 6Nivolumab 5pembrolizumab 4Gemcitabine 4Cisplatin 3regorafenib 2fludarabine 2Sorafenib 2Paclitaxel 2Oxaliplatin 2Leucovorin 2Irinotecan 2Fluorouracil 2Drug Therapy 2Cyclophosphamide 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1temsirolimus 1spartalizumab 1sonidegib 1selinexor 1sargramostim 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1pazopanib 1olutasidenib 1olaparib 1motexafin gadolinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × capmatinib × Gastrointestinal × Clear all
NCT02386826 2023-09-21

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

SCRI Development Innovations, LLC

Phase 1 Completed
65 enrolled
CNSGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Glioblastoma, Colorectal Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡